Triptans: Independent Evidence on Migraine, Heart Risk & Safety

Table of contents

• Evidence summary
• What triptans are
• How they work
• What they are prescribed for
• What works and what does not
• Benefits by claim
• Risks and all side effects
• All interactions
• Who should avoid triptans
• Dosage and how to take them
• Follow the money: who makes them and who funded the evidence
• Related research
• Frequently asked questions
• Sources and funding notes

Evidence summary

Independent evidence and credibility scorecard

Independence tiers: 1 = regulator or government body; 2 = academic or Cochrane team with no declared commercial funding for the work; 3 = independent authors analysing mostly manufacturer-run trials, or minor declared industry ties; 4 = manufacturer-funded or manufacturer-authored. Credibility runs from A (highest) to D.

Of the twelve scorecard rows, six are US sources (the FDA and NLM records, CMS, Evans, Orlova, Wang and Deighton, the last with Canadian co-authors), two are UK (the Cochrane reviews, plus the Danish and UK authors of the BMJ network meta-analysis), one is Danish (Petersen), one Norwegian (Harris) and two Canadian (Marchenko, Thorlund). The safety signal on the heart therefore comes largely from US and Danish data, and the pregnancy data from Norwegian and Canadian pooled cohorts.

What triptans are

Triptans are a class of prescription medicines taken as tablets, orally disintegrating tablets, nasal sprays or injections to treat a migraine attack. The labels we opened group them as 5-HT1 agonists and forbid taking two of them, or a triptan and an ergot medicine, within 24 hours of each other (FDA Imitrex tablet label (openFDA)). The main members in the sources we opened were:

• Sumatriptan. The first triptan. Imitrex injection was approved by the US FDA on 28 December 1992 (NDA 020080, sponsor GlaxoSmithKline) (Drugs@FDA NDA 020080); Imitrex tablets on 1 June 1995 (NDA 020132, GlaxoSmithKline) (Drugs@FDA NDA 020132). Generics are sold by many companies. A combination tablet of sumatriptan with naproxen also exists (it appears in the CMS NADAC comparison data).
• Rizatriptan. Maxalt, first approved in the US on 29 June 1998; the sponsor is now listed as Organon (openFDA Drugs@FDA brand records).
• Eletriptan. Relpax, approved on 26 December 2002; sponsor listed as Upjohn, manufacturer Viatris Specialty (openFDA Drugs@FDA brand records).
• Zolmitriptan, naratriptan, almotriptan and frovatriptan were also compared in the pooled analyses we reviewed (Karlsson et al., BMJ 2024; Thorlund et al. 2017).

In the UK the medicines are regulated by the MHRA; we could not open a UK product page, so we give US regulatory facts only.

How they work

We did not open a mechanistic source for this article, so we limit ourselves to what the labels and trials show. The label treats triptans as serotonin (5-HT1) agonists (FDA Imitrex tablet label (openFDA)). The label list of banned conditions (coronary vasospasm, peripheral vascular disease, ischaemic bowel disease, uncontrolled high blood pressure) is consistent with a drug that can narrow blood vessels, though that is our inference from the contraindications and not a statement we found in the label. In humans, what is proven is that the drugs relieve attack pain and related symptoms within hours (Derry et al., Cochrane 2012). Whether the effect arises mainly from blood-vessel action or from nerve-signalling effects is not something the trials we reviewed were designed to answer.

Two practical points are proven. First, timing matters: dosing earlier, while pain was still mild, did better than waiting (Derry et al., Cochrane overview 2014). Second, triptans are for the attack. They do not reduce how often attacks occur (MedlinePlus).

What they are prescribed for

• Acute migraine attacks in adults, the licensed use in the labels we opened (FDA Imitrex tablet label (openFDA)).
• Cluster headache. A separate Cochrane review of triptans for acute cluster headache exists (Law et al., Cochrane 2013); we list it but did not open its results.
• Children and adolescents are covered by a separate Cochrane review of drugs for acute migraine in that age group (Richer et al., Cochrane 2016); we did not open its results, and the sources we did open cover adults.

What works and what does not

Benefits by claim

"How well do triptans actually work?"

Better than many patients expect from the headline numbers, and worse than the word "migraine drug" implies. The Cochrane review of oral sumatriptan combined 61 trials with 37,250 participants. For 50 mg, NNT was 6.1 for being pain free at 2 hours, 7.5 for headache relief at 1 hour and 4.0 for headache relief at 2 hours. For 100 mg the NNTs were 4.7, 6.8 and 3.5 respectively. Sustained relief over 24 hours was harder: NNT 9.5 and 6.0 for 50 mg, 6.5 and 5.2 for 100 mg (Derry et al., Cochrane 2012). In plain English: if 100 people took 100 mg, roughly 21 more would be pain free at 2 hours than if they had taken placebo (100 divided by 4.7). The review's overview put the figures at 28% against 11% for oral 50 mg (Derry et al., Cochrane overview 2014).

"Which triptan is strongest?"

The 2024 BMJ network meta-analysis compared all licensed oral drugs for acute migraine across 137 trials. Every active drug beat placebo for 2-hour pain freedom (odds ratios from 1.73 for naratriptan to 5.19 for eletriptan). Head to head, eletriptan was best, then rizatriptan, sumatriptan and zolmitriptan (Karlsson et al., BMJ 2024). An earlier Bayesian analysis of 74 triptan trials (Thorlund et al. 2014) also put eletriptan first; we cite it only as a cross-check because its record showed no funding statement or affiliations. Because the comparisons are indirect for many pairs, an individual may do better on a "lower-ranked" triptan.

"Do the newer drugs replace triptans?"

Not on the 2024 evidence. The four leading triptans outperformed lasmiditan, rimegepant and ubrogepant on 2-hour pain freedom, and the authors suggested the best triptans belong on the WHO Essential Medicines List (Karlsson et al., BMJ 2024). The newer drugs may still matter for people who cannot take a triptan, which is the practical point of the contraindications below. Several authors of that paper disclosed ties to makers of the newer drugs.

"Does injected or nasal sumatriptan work better than tablets?"

Injected sumatriptan had the strongest effect and the fastest onset, at the price of more adverse events and higher cost (Derry et al., Cochrane overview 2014). Injection-site reactions were reported by 59% of people on the injection against 24% on placebo in the label of the generic injection (FDA sumatriptan injection label (openFDA)).

Risks and all side effects

Common side effects

The tablet label lists, at 2% or more and above placebo: tingling (paraesthesia), warm or cold sensations, other atypical sensations, chest, neck, throat or jaw pain or pressure, other pressure or pain, vertigo and fatigue (FDA Imitrex tablet label (openFDA)). MedlinePlus adds flushing, drowsiness, dizziness, upset stomach and nausea (MedlinePlus). In the Cochrane data, adverse events were mostly transient and mild, and rose with dose (Derry et al., Cochrane 2012).

How big is the heart risk in practice?

The two largest datasets we opened give different pictures because they ask different questions.

• General users. In 429,612 Danish first-time triptan users, 11 (0.003%) had a heart attack and 18 (0.004%) an ischaemic stroke in the windows around their first prescription (the case-crossover design compares the 2 weeks before each event with earlier reference periods). Compared with reference periods, the odds ratios were about 3 (heart attack 3.3, 95% CI 1.0 to 10.9; ischaemic stroke 3.2, 1.3 to 8.1). Cases had a median age of about 60 and a high-risk cardiovascular profile. The authors concluded absolute risk was very low in people with low baseline cardiovascular risk (Petersen et al., JAMA Neurology 2024).
• People with or at high risk of vascular disease. In 3,518 triptan users matched to 3,518 non-users (median age 55), major adverse cardiovascular events at 60 days were 1.48% against 0.37% (RR 4.00, 2.24 to 7.14). Deaths were 5 in each group (Wang et al., Mayo Clinic Proceedings 2024). That is an observational estimate: matching cannot remove every difference between people who are and are not prescribed a triptan.

A short 2025 commentary in the Drug and Therapeutics Bulletin 2025 is headed "Very small risk of stroke and MI associated with triptans"; we saw only its title. Taken together, the sources agree on direction (risk goes up) and on who carries it (older people with vascular risk), which is exactly the group the label tries to exclude.

Serious adverse events overall

A 141-trial network meta-analysis found sumatriptan, eletriptan, rizatriptan, zolmitriptan and sumatriptan-naproxen were linked to higher odds of any adverse event than placebo, but triptans were not linked to higher odds of serious adverse events (Thorlund et al. 2017). Two of its authors have Pfizer affiliations.

Medication overuse headache

The label warns that using acute migraine drugs on 10 or more days a month can worsen headaches and that withdrawal of the overused drug may be needed (FDA Imitrex tablet label (openFDA)). MedlinePlus advises no more than 10 days a month of any headache medicine and to call a doctor if an attack medicine is needed for more than 4 headaches a month (MedlinePlus). A pooled analysis of 29 studies found triptans carried a lower relative risk of medication overuse headache than simple analgesics (RR 0.65) and opioids (RR 0.35, limited evidence) (Thorlund et al. 2016), but the authors included Pfizer-affiliated staff. A literature review funded by Biohaven reported that triptan overusers withdrew more successfully than opioid or combination analgesic overusers (P under 0.0001) (Deighton et al., BMC Neurology 2021). Both papers have makers of competing products behind them, so we treat them as supporting, not central.

All interactions

• MAO-A inhibitors: the label contraindicates use during, or within 2 weeks of, an MAO-A inhibitor (FDA Imitrex tablet label (openFDA)).
• Another triptan or ergot-type medicine: not within 24 hours of each other (FDA Imitrex tablet label (openFDA)).
• SSRIs, SNRIs and tricyclic antidepressants: the label notes a higher risk of serotonin syndrome and says to stop the triptan if it is suspected (FDA Imitrex tablet label (openFDA)). See the next section for how large that risk looks in the data.
• Severe liver disease: contraindicated; with mild to moderate impairment the maximum single dose is 50 mg (FDA Imitrex tablet label (openFDA)).

We did not open an interaction source covering CYP enzymes, over-the-counter products or herbal products for rizatriptan or eletriptan, so those are not summarised.

The serotonin syndrome question

In 2006 the FDA issued an alert that combining triptans with SSRIs or SNRIs could cause life-threatening serotonin syndrome. The American Headache Society position paper reviewed the 29 cases behind it plus 11 later case reports. All 40 were Class IV evidence (the weakest class). Only 10 of the 29 FDA cases met the Sternbach criteria, and none met the Hunter criteria. The authors concluded the data were too limited to establish a risk, did not justify restricting triptans with SSRIs or SNRIs, and advised clinicians to watch for signs and report suspected cases (Evans et al., AHS position paper 2010).

A later cohort of 47,968 triptan users, of whom 19,017 were also prescribed an SSRI or SNRI (30,928 person-years), found 2 definite serotonin syndrome cases: 0.6 per 10,000 person-years (95% CI 0.0 to 1.5). Adding 5 possible cases gave 2.3 per 10,000 person-years (95% CI 0.6 to 3.9) (Orlova et al., JAMA Neurology 2018). So the myth is "common and dangerous". The better-supported picture is "rare, hard to diagnose, and worth watching for". The label warning has not been removed, and our sources do not settle whether the true risk is zero. Seek urgent help for agitation, confusion, fever, sweating, stiffness, twitching or a racing heart.

Who should avoid triptans

• Coronary artery disease, coronary vasospasm, prior heart attack, angina: contraindicated (FDA Imitrex tablet label (openFDA)).
• Prior stroke or TIA, hemiplegic or basilar migraine: contraindicated (FDA Imitrex tablet label (openFDA)).
• Peripheral vascular disease, ischaemic bowel disease, uncontrolled hypertension, Wolff-Parkinson-White syndrome: contraindicated (FDA Imitrex tablet label (openFDA)).
• Several cardiovascular risk factors without known disease: label advises a cardiac evaluation first (FDA sumatriptan injection label (openFDA)). The 2024 BMJ authors also urged caution in high-risk patients (Karlsson et al., BMJ 2024).
• Severe liver impairment: contraindicated (FDA Imitrex tablet label (openFDA)).
• People on MAO-A inhibitors: see interactions.
• People who need attack medicine on 10 or more days a month: that is a reason to talk to the prescriber about prevention, since overuse can worsen headache (FDA Imitrex tablet label (openFDA)).

Pregnancy and breastfeeding

The sumatriptan labels describe a pregnancy registry with 626 exposed infants and fetuses. Major birth defects were 4.2% after first-trimester exposure. The label calls the registry insufficient to support definitive conclusions (FDA Imitrex tablet label (openFDA)). It also notes that women with migraine may have a higher risk of pre-eclampsia (FDA sumatriptan injection label (openFDA)).

A meta-analysis of one case-control and five cohort studies (4,208 triptan-exposed infants) found no significant difference in major malformations against women with migraine who did not use triptans (OR 0.84, 95% CI 0.61 to 1.16), nor in prematurity (OR 0.90, 0.35 to 2.30). Against healthy women the malformation odds ratio was 1.18 (0.97 to 1.44), and spontaneous abortion odds were higher (OR 3.54, 2.24 to 5.59), but migraine without triptans also carried a malformation OR of 1.41 (1.11 to 1.80) compared with healthy women. That pattern suggests the migraine, and not only the drug, may explain part of the signal (Marchenko et al., Headache 2015). The authors' record showed no funding statement. In 10,167 Norwegian children of mothers with migraine, prenatal triptan exposure was not linked to ADHD (hazard ratio 1.16, 0.78 to 1.74 against migraine in pregnancy without triptans) (Harris et al., JAMA Network Open 2022).

These data are reassuring but not conclusive, and the registry is the maker's. We did not open breastfeeding guidance beyond MedlinePlus, which tells readers to inform their doctor if breastfeeding (MedlinePlus).

Dosage and how to take them

These are label doses, not advice. The Imitrex tablet label lists single doses of 25, 50 or 100 mg, a second dose no sooner than 2 hours after the first, and a maximum of 200 mg in 24 hours; the maximum single dose is 50 mg in mild to moderate liver impairment (FDA Imitrex tablet label (openFDA)). The injection label lists up to 6 mg subcutaneously, with a 24-hour maximum of 12 mg given as two 6 mg injections at least one hour apart, and a second injection only if there was some response to the first (FDA sumatriptan injection label (openFDA)). MedlinePlus says to take it at the first sign of a migraine and not to take more, or more often, than prescribed (MedlinePlus). We did not open label doses for rizatriptan, eletriptan or zolmitriptan.

Follow the money: who makes them and who funded the evidence

Who makes and sells them

• Sumatriptan: developed and first marketed by GlaxoSmithKline, which is the sponsor of the original injection (1992) and tablet (1995) applications in Drugs@FDA (Drugs@FDA NDA 020080; Drugs@FDA NDA 020132). The FDA database lists dozens of generic (ANDA) applications for sumatriptan, including naproxen combinations; the earliest we saw dates from 2007 (openFDA Drugs@FDA generic applications). No single company now controls the market.
• Rizatriptan (Maxalt): sponsor Organon. Eletriptan (Relpax): sponsor Upjohn, manufacturer Viatris Specialty. Zolmitriptan (Zomig): current FDA records list Amneal and IPR as application sponsors (openFDA Drugs@FDA brand records). We could not verify parent-company or ownership details beyond these FDA fields.
• Newer competitors are the gepants and lasmiditan. A Biohaven-funded paper on triptan switching is in our scorecard (Deighton et al., BMC Neurology 2021); the labels we opened did not describe Biohaven's products, so we make no claims about them.

Price and generics

A May 2021 snapshot of the US National Average Drug Acquisition Cost (a government survey of what pharmacies pay) listed sumatriptan 50 mg tablets at about US$0.55 per unit and 100 mg tablets at about US$0.60 per unit; the sumatriptan 85 mg plus naproxen 500 mg combination was about US$30.05 per unit and the 6 mg/0.5 mL injection about US$81.08 per unit (CMS NADAC comparison data). The record did not state the pricing unit, and the data are more than four years old, so treat these as relative orders of magnitude: generic tablets cost cents, while the injection and combination products cost many times more. We could not obtain current UK or US retail prices, or the price of branded Imitrex, Maxalt or Relpax.

Who funded the evidence

• The Cochrane sumatriptan reviews. The oral review included 61 trials. Of these, 38 were supported directly by sumatriptan's manufacturers (GlaxoSmithKline, Glaxo Wellcome or Glaxo), 20 by another drug company, and 3 reported no company involvement. Some data came from results summaries on the manufacturer's website, and the authors requested unpublished data from GSK (full text). The 2014 overview declares that R. Andrew Moore has consulted for various pharmaceutical companies and received lecture fees (full text); we did not verify whether the 2012 review names GlaxoSmithKline specifically. The 2014 overview lists the Oxford Pain Relief Trust as institutional support, with Lifting The Burden and the International Headache Society paying for editorial and peer review (full text).
• The "industry data" debate. Cochrane's 2014 commercial sponsorship policy bars commercial sponsors from funding or conducting a review and bars authors employed by an interested company, while allowing authors with some industry ties if most authors are free of them. It says authors of included studies must declare that and others should extract their data. The policy page says it was due to retire on 1 October 2025 and was partly superseded by a 2020 policy (Cochrane commercial sponsorship policy). The sumatriptan reviews follow the rule that matters most (no sponsor funded the review) but depend on a trial base mostly run by the manufacturers. We could not verify from the pages we opened whether Cochrane has formally flagged these particular reviews.
• The network meta-analysis. Funded by the NIHR Oxford Health Biomedical Research Centre and a Lundbeck Foundation professor grant, with a statement that the funders had no role; author disclosures include fees from Pfizer, Lundbeck, Teva and Angelini (Karlsson et al., BMJ 2024).
• The safety studies. Orlova and colleagues: NIH grant (Orlova et al., JAMA Neurology 2018). Petersen: no funding statement shown in the record; Wang: Europe PMC lists a US government AHRQ contract (Petersen et al., JAMA Neurology 2024; Wang et al., Mayo Clinic Proceedings 2024). The Norwegian cohort: Dam Foundation grant to the first author (Harris et al., JAMA Network Open 2022). The overuse papers have Pfizer affiliations (Thorlund et al. 2016) or are Biohaven-funded (Deighton et al., BMC Neurology 2021).

Documented integrity events

We found no regulatory action, recall or lawsuit about triptans in the sources we opened, and we did not run a dedicated search for litigation or warning letters, so the absence of any is not evidence there were none.

Related research

• Amitriptyline: Independent Evidence on Pain, Migraine, IBS, Risks & Withdrawal
• Propranolol for Anxiety: Independent Evidence, Overdose Risk & Side Effects
• Atenolol and Beta-Blockers: Independent Evidence on Hypertension
• Magnesium Forms: Absorption, Benefits, Doses and Safety
• CoQ10: Ubiquinone vs Ubiquinol, Heart Health, and Statin Muscle Pain
• Sertraline: Independent Evidence on Depression, Side Effects & Withdrawal
• MAOI Antidepressants: Independent Evidence, Diet & Interactions
• Hypertension: Accurate Measurement, Treatment, Safety and Evidence Funding
• Stroke: Emergency Signs, Ischaemic and Haemorrhagic Types, Treatment and Recovery
• Transient Ischaemic Attack: TIA Warning Signs, Assessment and Stroke Prevention
• Hypertension in Pregnancy & Pre-eclampsia: Independent Evidence

Frequently asked questions

Sources and funding notes

What we could not verify: current UK guidance (NICE and the BNF blocked access); UK or EU product information; label doses and interactions for rizatriptan, eletriptan and zolmitriptan; breastfeeding transfer data; a mechanistic review; whether Cochrane has flagged the Derry and Moore reviews under its sponsorship policy; the funding of the American Headache Society; current retail prices; any litigation or warning letters; and the author countries of the BMJ, Marchenko and Thorlund papers. The FDA 2006 alert itself could not be opened, so we describe it through the American Headache Society paper. There is no dedicated migraine page on Pure City Research to link to.

1. Derry et al., Cochrane 2012 (full text) — role: main efficacy evidence for oral sumatriptan; funder: Oxford Pain Relief Trust (UK charity), with 38 of 61 trials manufacturer-supported.
2. Derry et al., Cochrane overview 2014 (full text) — role: route comparison and adverse-event rates; funder: Oxford Pain Relief Trust; editorial costs paid by Lifting The Burden and the International Headache Society.
3. Karlsson et al., BMJ 2024 — role: ranking of triptans and newer drugs; funder: NIHR Oxford Health BRC and a Lundbeck Foundation professor grant, author disclosures listed.
4. FDA Imitrex tablet label (openFDA) — role: tablet label (contraindications, doses, registry); funder: US government regulator; efficacy and registry data come from the maker.
5. FDA sumatriptan injection label (openFDA) — role: injection label (generic injection, Caplin Steriles); funder: US government regulator.
6. MedlinePlus — role: patient information; funder: US National Library of Medicine, revised 15 June 2025.
7. Drugs@FDA NDA 020132 and Drugs@FDA NDA 020080 — role: approval dates and sponsor; funder: US government.
8. openFDA Drugs@FDA generic applications and openFDA Drugs@FDA brand records — role: generic counts and brand sponsors; funder: US government (unvalidated openFDA data).
9. CMS NADAC comparison data — role: acquisition costs; funder: US government, May 2021 snapshot.
10. Evans et al., AHS position paper 2010 — role: appraisal of the 2006 FDA alert; funder: no statement in record.
11. Orlova et al., JAMA Neurology 2018 — role: serotonin syndrome incidence; funder: NIH grant UL1 TR000170.
12. Petersen et al., JAMA Neurology 2024 — role: stroke and heart attack after starting triptans; funder: no statement in record.
13. Wang et al., Mayo Clinic Proceedings 2024 — role: cardiovascular events in high-risk patients; funder: no statement in record.
14. Drug and Therapeutics Bulletin 2025 — role: commentary, title only; funder: not shown.
15. Marchenko et al., Headache 2015 — role: pregnancy meta-analysis; funder: no statement in record.
16. Harris et al., JAMA Network Open 2022 — role: ADHD in offspring; funder: Dam Foundation grant to first author.
17. Thorlund et al. 2016 and Thorlund et al. 2017 — role: overuse headache risk and tolerability; funder: no statement in records, two Pfizer-affiliated authors.
18. Deighton et al., BMC Neurology 2021 — role: switching and overuse review; funder: Biohaven.
19. Cochrane commercial sponsorship policy — role: rules on commercial sponsorship of Cochrane reviews; funder: Cochrane (UK/international).
20. Law et al., Cochrane 2013, Richer et al., Cochrane 2016 and Thorlund et al. 2014 — role: titles only or cross-check; funder: not verified.

Educational research reviewed 9 October 2026. This article is not medical advice; talk to a qualified clinician or pharmacist before starting, stopping or combining treatments.